The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial.
The effect of perioperative probiotics treatment for colorectal cancer: short-term outcomes of a randomized controlled trial.
复制标题
围手术期益生菌治疗结直肠癌的效果：随机对照试验的短期结果。
DOI：
10.18632/oncotarget.7045
复制
发表时间：
2016-02-16
期刊：
影响因子：
--
通讯作者：
Ma Y
中科院分区：
文献类型：
--
作者：
Yang Y;Xia Y;Chen H;Hong L;Feng J;Yang J;Yang Z;Shi C;Wu W;Gao R;Wei Q;Qin H;Ma Y
本研究旨在评价围手术期益生菌治疗对局限性结直肠癌（CRC）患者的抗感染作用。从2011年11月至2012年9月，共有60名诊断为CRC的患者被随机分配接受益生菌（n = 30）或安慰剂（n = 30）治疗。研究了手术和术后临床结果，包括肠道清洁度、首次排气天数、排便、流质饮食、固体饮食、发热持续时间、平均心率、腹腔引流时间、抗生素治疗时间、血液指标变化、感染性和非感染性并发症发生率、术后住院时间和死亡率。患者人口统计学在益生菌治疗组和安慰剂组之间没有显著差异（p > 0.05）。在益生菌治疗的患者中，第一次排气的天数（3.63对3.27，p = 0.0274）和第一次排便的天数（4.53对3.87，p = 0.0268）显著改善。益生菌组腹泻发生率（26.67%，8/30）显著低于安慰剂组（53.33%，16/30）（p = 0.0352）。其他感染性和非感染性并发症发生率无统计学差异（p > 0.05），包括伤口感染、肺炎、尿路感染、吻合口瘘和腹胀。结论：围手术期应用益生菌对局限性结直肠癌切除术患者肠功能的恢复有显著影响，对减少菌血症等短期感染性并发症具有重要的临床意义。
This study was designed to mainly evaluate the anti-infective effects of perioperative probiotic treatment in patients receiving confined colorectal cancer (CRC) respective surgery. From November 2011 to September 2012, a total of 60 patients diagnosed with CRC were randomly assigned to receive probiotic (n = 30) or placebo (n = 30) treatment. The operative and post-operative clinical results including intestinal cleanliness, days to first - flatus, defecation, fluid diet, solid diet, duration of pyrexia, average heart rate, length of intraperitoneal drainage, length of antibiotic therapy, blood index changes, rate of infectious and non-infectious complications, postoperative hospital stay, and mortality were investigated. The patient demographics were not significantly different (p > 0.05) between the probiotic treated and the placebo groups. The days to first flatus (3.63 versus 3.27, p = 0.0274) and the days to first defecation (4.53 versus 3.87, p = 0.0268) were significantly improved in the probiotic treated patients. The incidence of diarrhea was significantly lower (p = 0.0352) in probiotics group (26.67%, 8/30) compared to the placebo group (53.33%, 16/30). There were no statistical differences (p > 0.05) in other infectious and non-infectious complication rates including wound infection, pneumonia, urinary tract infection, anastomotic leakage, and abdominal distension. In conclusion, for those patients undergoing confined CRC resection, perioperative probiotic administration significantly influenced the recovery of bowel function, and such improvement may be of important clinical significance in reducing the short-term infectious complications such as bacteremia.